Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company's primary focus is on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy drug candidates.
Type | Public | |
Founded | 1980 | |
HQ | Cambridge, MA, US | Map |
Website | sarepta.com | |
Employee Ratings | More |
USD | |
---|---|
Market capitalization (12-May-2022) | 5.5b |
Closing stock price (12-May-2022) | 63.3 |
Cash (30-Jun-2021) | 1.7b |
EV | 4.1b |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 54.2m | 46.4m | 30.6m | 24.5m | 38.0m | 167.9m | 156.2m | 273.6m | 49.1m | 102.8m | 52.3m | 74.4m | 69.5m | 55.8m | 38.0m | 111.8m | 395.1m | 274.7m | 168.3m | 617.6m | 557.2m | 410.4m | 209.7m | 732.2m | 808.6m | 724.8m | 1.8b | 1.6b | 1.5b | 1.5b | 1.7b |
Accounts Receivable | 10.9m | 4.3m | 5.1m | 7.2m | 2.5m | 5.7m | 3.8m | 6.7m | 7.8m | 5.2m | 3.4m | 2.4m | 2.4m | 2.7m | 4.0m | 4.0m | 4.0m | 12.3m | 17.8m | 24.8m | 39.8m | 43.0m | 48.6m | 50.5m | 57.0m | 68.0m | 106.9m | 104.0m | 121.8m | 118.2m | 127.5m |
Prepaid Expenses | 943.0k | 1.3m | 1.9m | 1.6m | 1.7m | 3.0m | 5.7m | 2.8m | 9.1m | 15.9m | 26.4m | 24.4m | 23.1m | 19.5m | 16.9m | 15.3m | 22.0m | 22.7m | 28.6m | 27.0m | 31.2m | 43.0m | 54.8m | 136.2m | 110.8m | 79.0m | |||||
Inventories | 2.9m | 30.4m | 41.8m | 64.7m | 99.4m | 104.1m | 115.8m | 140.5m | 156.6m | 166.4m | 173.2m | 179.7m | 220.1m | 240.3m | 268.8m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (2.3m) | (121.3m) | (112.0m) | (135.8m) | (220.0m) | (267.3m) | (50.7m) | (361.9m) | (715.1m) | (554.1m) |
Depreciation and Amortization | 1.3m | 1.5m | 1.3m | 3.7m | 5.2m | 5.6m | 8.1m | 12.2m | 30.5m | 26.9m |
Inventories | (12.8m) | (70.8m) | (41.8m) | (45.9m) | (60.6m) | |||||
Accounts Payable | 9.5m | 10.8m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 3.1m | (908.0k) | (17.7m) | (9.7m) | (59.2m) | (42.1m) | (61.1m) | (103.2m) | (28.3m) | (62.1m) | (91.4m) | (61.6m) | (103.4m) | (155.3m) | (59.8m) | (122.1m) | (178.8m) | 84.1m | 21.0m | (26.7m) | (35.4m) | (144.6m) | (221.0m) | (76.6m) | (353.0m) | (479.4m) | (17.5m) | (168.3m) | (364.8m) | (167.2m) | (248.7m) |
Depreciation and Amortization | 490.0k | 763.0k | 353.0k | 715.0k | 1.1m | 451.0k | 711.0k | 998.0k | 523.0k | 1.5m | 2.5m | 1.3m | 2.6m | 3.9m | 1.4m | 2.9m | 3.9m | 1.6m | 3.4m | 6.0m | 2.3m | 5.1m | 8.7m | 6.4m | 14.1m | 22.3m | 6.5m | 13.0m | 19.6m | 8.9m | 17.4m |
Inventories | (2.9m) | (17.6m) | (28.9m) | (51.9m) | (15.8m) | (20.5m) | (32.2m) | (15.0m) | (31.1m) | (40.9m) | (1.8m) | (8.3m) | (48.7m) | (8.4m) | (36.8m) | ||||||||||||||||
Accounts Payable | (294.0k) | 1.9m | 1.7m | (4.3m) | (4.5m) | (5.1m) | (566.0k) | (3.1m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 2.1 x |
Sarepta Therapeutics has 4.09k Twitter Followers. The number of followers has increased 0.9% month over month and increased 3.2% quarter over quarter
769
Tweets
59
Following
4.1k
Followers
19
Tweets last 30 days
8.5
Avg. likes per Tweet
100%
Tweets with engagement
When was Sarepta Therapeutics founded?
Sarepta Therapeutics was founded in 1980.
Who are Sarepta Therapeutics key executives?
Sarepta Therapeutics's key executives are Douglas S. Ingram, Diane Berry and Louise Rodino-Klapac.
How many employees does Sarepta Therapeutics have?
Sarepta Therapeutics has 743 employees.
Who are Sarepta Therapeutics competitors?
Competitors of Sarepta Therapeutics include Lannett, Ionis Pharmaceuticals and Moderna.
Where is Sarepta Therapeutics headquarters?
Sarepta Therapeutics headquarters is located at 215 First St, Cambridge.
Where are Sarepta Therapeutics offices?
Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations.
How many offices does Sarepta Therapeutics have?
Sarepta Therapeutics has 12 offices.
Receive alerts for 300+ data fields across thousands of companies